Neurophet Unveils Solutions Including 'Neurophet AQUA AD' at AAIC 2025

[Financial News] Neurophet announced on the 24th that it will participate in the Alzheimer's Association International Conference (AAIC) 2025 to unveil its major brain imaging analysis AI solutions.
Bin Jun-gil, Co-CEO of Neurophet, will give a presentation on 'Neurophet in the Era of Alzheimer's Paradigm Shift: The Journey to IPO and Beyond' at this conference.
At this conference, Neurophet will unveil the software 'Neurophet AQUA AD' that can monitor the prescription, treatment effects, and side effects of dementia treatments.
Neurophet AQUA AD is a solution that provides precise brain imaging analysis functions throughout the administration of anti-amyloid antibody treatments by quantitatively analyzing MRI (Magnetic Resonance Imaging) and PET (Positron Emission Tomography) images.
As the pharmaceutical and bio industries are accelerating the development of Alzheimer's treatments, the importance of introducing solutions that can precisely manage prescriptions, treatment effects, and side effects is being highlighted.
In particular, Alzheimer's treatments such as Leqembi (ingredient name: Lecanemab) and Qysnra (ingredient name: Donanemab) require essential side effect monitoring, and global demand and expectations for Neurophet AQUA AD, which can analyze brain imaging biomarkers related to side effects, are increasing.
Through booth exhibitions, Neurophet will introduce Neurophet AQUA AD along with △Brain Neurodegeneration Imaging Analysis Software 'Neurophet AQUA' △PET Image Quantitative Analysis Software 'Neurophet SCALE PET'.
Neurophet will engage in partnering for business development cooperation with global big pharma and potential clients through its participation in AAIC 2025. Additionally, it will hold meetings with key opinion leaders in the neurology field to emphasize the differentiated competitiveness of Neurophet products and build a collaborative network.
CEO Bin stated, "Neurophet AQUA AD is gaining attention as a collaborative partner for various domestic and international companies in the brain imaging biomarker field," and added, "Through this participation in AAIC 2025, we plan to further accelerate global development cooperation for major products including Neurophet AQUA AD."
Meanwhile, AAIC 2025 is an international conference attended by dementia researchers and neurology clinicians, held in Toronto, Canada. This conference will take place from the 27th to the 31st for five days, according to local time in Canada.


vrdw88@fnnews.com Kang Jung-mo Reporter